Victoza is not semaglutide. Victoza’s active ingredient is liraglutide, a different medication. Both liraglutide and semaglutide belong to the same drug class, known as GLP-1 receptor agonists, which is why they’re often confused. They work in a similar way, but they are distinct molecules with different dosing schedules, brand names, and clinical profiles.
How Victoza and Semaglutide Are Related
Victoza (liraglutide) and semaglutide-based drugs like Ozempic and Wegovy are all GLP-1 receptor agonists. These medications mimic a gut hormone that helps regulate blood sugar and appetite. They share similar benefits and similar side effects, but they are not interchangeable.
Here’s how the brand names map to each active ingredient:
- Liraglutide: Victoza (for type 2 diabetes), Saxenda (for weight management)
- Semaglutide: Ozempic (for type 2 diabetes), Wegovy (for weight management), Rybelsus (oral tablet for type 2 diabetes)
The pattern is the same for both drugs: one brand treats diabetes, and a separate brand at a different dose is approved for weight loss. Victoza was first approved by the FDA in January 2010, making it the older of the two. You should not use a liraglutide product and a semaglutide product together, or combine any two GLP-1 receptor agonists.
The Key Difference: Daily vs. Weekly Injections
The most practical difference between the two is how often you take them. Victoza is a daily injection, with doses ranging from 0.6 mg up to 1.8 mg per day. Semaglutide (Ozempic/Wegovy) is a once-weekly injection, with doses starting at 0.25 mg and going up to 2.4 mg per week.
Semaglutide lasts longer in the body because of how the molecule is designed. It binds to a protein in your blood called albumin, which extends its half-life to roughly 160 hours, or about a week. Liraglutide clears the body faster, which is why it needs to be injected every day. For many people, a weekly injection is simply more convenient.
Blood Sugar Control
Both drugs lower blood sugar effectively in people with type 2 diabetes, but semaglutide has a measurable edge. A 2025 meta-analysis pooling data from multiple trials found that semaglutide reduced A1C levels significantly more than liraglutide. In concrete terms, the difference averaged over half a percentage point in favor of semaglutide, which is clinically meaningful when you’re trying to get blood sugar into a target range.
Weight Loss
This is where many people expect a big gap, but the pooled research tells a more nuanced story. When comparing the diabetes doses of both drugs (Victoza vs. Ozempic), the meta-analysis found no statistically significant difference in weight change or BMI reduction. Individual trials have sometimes shown an advantage for semaglutide, but across all available studies, the difference wasn’t large enough to be definitive.
The weight management versions of these drugs, Saxenda and Wegovy, use higher doses than their diabetes counterparts, and Wegovy is generally associated with greater weight loss in that setting. But comparing Victoza to Ozempic at their standard diabetes doses, the weight loss gap is smaller than most people assume.
Heart Health
Both liraglutide and semaglutide have been tested in large cardiovascular outcome trials involving thousands of patients with type 2 diabetes and heart disease risk.
In the LEADER trial, liraglutide reduced the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) by 13% compared to placebo over roughly four years. In the SUSTAIN 6 trial, subcutaneous semaglutide reduced the same composite outcome by 26% over two years. Both results confirmed these drugs are safe for the heart, and both showed meaningful benefit, with semaglutide posting the larger percentage reduction in its trial.
Side Effects: Gut Symptoms Are Common With Both
Nausea, diarrhea, and vomiting are the most frequent complaints across all GLP-1 drugs, and both liraglutide and semaglutide cause them. However, their rates differ. A large Bayesian network meta-analysis estimated that nausea occurs in about 21.5% of people taking semaglutide, compared to 15% with liraglutide. Diarrhea rates were 10.6% for semaglutide versus lower odds with liraglutide, and semaglutide also carried a higher risk of vomiting compared to some other drugs in the class.
In short, semaglutide tends to cause more gastrointestinal side effects than liraglutide. Both drugs typically start at a low dose and increase gradually to help your body adjust, which reduces (but doesn’t eliminate) these symptoms. Most people find the nausea improves over the first few weeks.
Which One Is Right for You
Choosing between Victoza and a semaglutide product depends on what you’re treating, your insurance coverage, and how you feel about daily versus weekly injections. Semaglutide offers stronger A1C reduction and the convenience of once-weekly dosing, but it also comes with higher rates of nausea and diarrhea. Liraglutide has a longer track record, having been on the market since 2010, and some people tolerate it better.
If you’re currently on Victoza and wondering whether switching to Ozempic or Wegovy would be worthwhile, the answer depends on your goals. For tighter blood sugar control or the convenience of fewer injections, semaglutide has clear advantages. If Victoza is working well and you’re tolerating it without issues, there may be no pressing reason to change.